N/A N=50 Effects of a Health Intervention on Fear of Hypoglycemia : a Pilot Study
Type 2 Diabetes Mellitus · Fear of Hypoglycemia · Health Education
Primary: Hypoglycemia Fear Behavioral — 59.60; 63.88; 57.52; 44.20 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=53 Study to Determine the Efficacy of Real-time CGM in Preventing Hypoglycemia Among Insulin-treated Patients With DM2 on Hemodialysis, Compared to Standard of Care (POC BG)
End-Stage Renal Disease · Type 2 Diabetes
Primary: Differences in Mean Percentage Time-in-hypoglycemia (< 70 mg/dL) — 1.24; 1.19 percentage of time in hypoglycemia
Phase 3 N=803 Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)
Migraine
Primary: Percentage of Participants Who Had Freedom From Pain at 2 Hours Post-Dose — 21.0; 32.4; 13.0 Percentage of participants — p=<0.0001
Phase 1 N=138 Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555)
Melanoma
Primary: Area Under the Concentration-Time Curve (AUC) of Pembrolizumab - Cohort A — 507; 480; 695 mg*day/L
Phase 3 N=805 Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
Primary: Overall Survival (OS) in All Participants (Co-primary Endpoint) — 17.2; 11.9 months — p=<0.0001
N/A N=329 Surveillance and Alert-based Multiparameter Monitoring to Reduce Worsening Heart Failure Events
Heart Failure
Primary: Number of Usable Worsening HF Events as Adjudicated by CEC — 69 Adjudicated Events
N/A N=453 We Are Here Now: a Multi-level, Multicomponent Sexual and Reproductive Health Intervention for American Indian Youth
Reproductive Behavior · Sexual Behavior
Primary: Change in Number of Protected Acts Using a Condom During Vaginal and/or Anal Sex in the Past 30 Days. — 0.31 proportion — p=<0.05
Phase 1 N=27 Safety, Tolerability and Pharmacokinetic Profiles of MOTREM (LR12) in Healthy Male Subjects
Healthy Subjects
Primary: Safety and Tolerability: the Number of Subjects Experiencing Treatment Emergent Adverse Events — 1; 0; 1; 1 Participants
N/A N=15 Simple Non-invasive Breathing Device to Improve Pulmonary Flow Pusatility in Single Ventricle Post Fontan
Single-ventricle
Primary: Change in Pulmonary Pulsatility Index — 51.6; 57.6 Ratio — p=0.1
N/A N=103 Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome
Cushing's Syndrome
Primary: Effectiveness of Osilodrostat — 23 Participants
N/A N=70 A Study of mDOT for Immunosuppressant Adherence in Solid Organ Transplant Recipients
Medication Adherence · Liver Transplantation · Kidney Transplantation
Primary: Medication Adherence Via Medication Level Variability Index (MLVI) — 23; 24; 10; 8 Participants
Phase 2 N=37 NB-001 in Children and Adolescents With 22q11 Deletion Syndrome
22q11 Deletion Syndrome
Primary: Safety and Tolerability of NB-001 — 18; 24; 14; 20 Participants
Phase 4 N=61 Neurocognitive Benefits of a Weight Management Program
Overweight and Obesity
Primary: Blood Oxygen Level-dependent (BOLD) Response to High-calorie Foods Cues Minus Neutral Objects in Left Anterior Cingulate Cortex — -0.05; -0.16 percent BOLD signal change
N/A N=91 Siyakhana Peer: Evaluating a Peer Recovery Coach Model to Reduce Substance Use Stigma in South African HIV Care
Substance-Related Disorders · Substance Use · Substance Use Disorders
Primary: Healthcare Worker Substance Use Stigma — 11.63; 9.95 score on a scale — p=0.023
Phase 4 N=104 Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Number of Adverse Events (AEs) — 45 Events